This study was conducted in collaboration with Professor Josko Osredkar and is titled "Clinical Significance of the TK1 specific Activity in the Early Detection of Ovarian Cancer". TK1 SA is determined by calculating the ratio of TK1 activity by TK-Liaison and TK1 protein by AroCell TK 210 ELISA. The study included 134 patients with ovarian tumors (72 benign and 62 malignant) and 64 healthy age-matched controls.

The study results revealed that TK1 SA, which complements traditional biomarkers such as CA 125 and HE4, significantly improved the sensitivity for early detection of benign and malignant ovarian cancer. The combination of various biomarkers provided a more comprehensive and accurate diagnostic approach. These findings have implications in proving the early detection rates and subsequent treatment outcomes for ovarian cancer patients.

Furthermore, the study observed the fluctuations in TK1 SA levels in relation to surgery and chemotherapy which provided valuable information for monitoring the effectiveness of treatment and assessing disease progression.

"We are delighted by the acceptance of our study in the Karger Oncology journal, and this will further widen the clinical applications of TK 210 ELISA," said Kiran Kumar Jagarlamudi, co-author and CSO at AroCell. "This research highlights the potential of TK1 SA as an additional tool in the early detection of ovarian cancer.

According to WHO, ovarian cancer is the eighth most common cause of cancer and cancer death in women. A major concern is that almost two-thirds of cases are typically diagnosed in the late stage as the symptoms are unspecific in the early stage of ovarian cancer.

For more information on the study, visit Karger Oncology journal.